CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors
Journal for ImmunoTherapy of Cancer · 2026-05 · 14 (5) · e014592
DOI: 10.1136/jitc-2025-014592 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 04.05.2026. Verfasst von Giuseppe Nardo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy giuseppe.nardo@istitutotumori.mi.it. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Immunity, Innate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Chimeric antigen receptor (CAR) therapies have revolutionized cancer immunotherapy, particularly in hematologic malignancies, but their efficacy in solid tumors remains limited. Key barriers include tumor antigen heterogeneity, on-target/off-tumor toxicity, impaired trafficking, and an immunosuppressive tumor microenvironment.
Methods
We conducted a narrative review of preclinical and clinical studies investigating CAR-engineered innate and innate-like immune cells, including CAR-natural killer, CAR-γδ T, CAR-natural killer T (NKT), and CAR-macrophages, focusing on their biological features, therapeutic potential, and current clinical development in solid tumors.
Results
These alternative platforms exhibit distinct advantages over conventional CAR-T cells, including reduced risk of severe toxicities, improved trafficking, overcoming antigen loss, and higher allogeneic potential. Emerging clinical data suggest favorable safety profiles, although limited persistence and variable efficacy remain key challenges. Advances in cell engineering, such as cytokine armoring and non-viral gene transfer, are further enhancing their therapeutic potential.
Conclusions
CAR-engineered innate and innate-like immune cells represent a promising next-generation strategy to overcome the limitations of conventional CAR-T therapies in solid tumors. Among these, CAR-NKT and CAR-γδ T cells may offer particular advantages for clinical translation, warranting further investigation in future trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy giuseppe.nardo@istitutotumori.mi.it.
- Unit of Immunotherapy and Anticancer Innovative Therapeutics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Unit of Melanoma Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Medical Oncology and Hematology Department, University of Milan, Milan, Italy.
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Zitieren
APA
Nardo, G., Putti, F., Indini, A., Del Vecchio, M., De Braud, F., Di Nicola, M., & De Santis, F. (2026). CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors. Journal for ImmunoTherapy of Cancer, 14(5), e014592. https://doi.org/10.1136/jitc-2025-014592
Vancouver
Nardo G, Putti F, Indini A, Del Vecchio M, De Braud F, Di Nicola M, et al. CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors. Journal for ImmunoTherapy of Cancer. 2026;14(5):e014592. doi:10.1136/jitc-2025-014592
BibTeX
@article{Nardo2026,
author = {Nardo, Giuseppe and Putti, Francesca and Indini, Alice and Del Vecchio, Michele and De Braud, Filippo and Di Nicola, Massimo and De Santis, Francesca},
title = {CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {5},
pages = {e014592},
doi = {10.1136/jitc-2025-014592}
}
EUVIMED